IceCure Medical

ICCM

Market cap $24.5M

The Company's participation at the Society of Breast Imaging Symposium and other upcoming medical conferences are timely as commercial momentum accelerates Cryoablation cost analysis study from Massachusetts General Hospital featuring ProSense® demonstrated 50% reduction in cost vs. lumpectomy won SBI 2026 Abstract Award CAESAREA, Israel, April 21, 2026 /PRNewswire/ -- IceCure Medical Ltd.

CAESAREA, Israel, March 26, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has entered into securities purchase agreements with healthcare focused institutional investors for the purchase and sale of 8,000,000 ordinary shares at a purchase price of $0.50 per share in a registered direct offering.

At a median follow-up of four years, 89.4% recurrence-free rate in patients with tumors ≤3 cm and no prior kidney cancer; 83.9% recurrence-free rate for general study population Full analysis of results to be presented at European Conference of Interventional Oncology 2026 in Basel, Switzerland Data supports broader commercial adoption of ProSense® as a minimally invasive treatment for small renal masses in markets where it is approved for kidney cancer, including the U.S. and Europe  CAESAREA, Israel, March 25, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced positive top-line results from its ICESECRET clinical trial of ProSense® for the treatment of small renal masses ("SRMs") in kidney cancer patients.

Meir Peleg brings over 20 years of financial leadership and experience including with Nasdaq listed companies IceCure intends to appoint Dr. Richard Fine as Medical Director CAESAREA, Israel, March 24, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the appointment of Mr.

IceCure Medical Ltd (ICCM) Q4 2025 Earnings Call Transcript

Record 4th quarter and full year sales of $1.3 million and $3.4 million, respectively Strong commercial momentum for ProSense® in the U.S. and globally following FDA clearance in low-risk breast cancer and medical society recommendations 30 hybrid commercial-clinical sites to be added for FDA approved post-marketing study in addition to growing pipeline of potential commercial customers IceCure Applies to Expand Regulatory Approval in Canada for ProSense® Cryoablation to Include the Treatment of Low-Risk Breast Cancer  Conference call to be held today at 11:00 am Eastern Time CAESAREA, Israel, March 17, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today reported record sales as of and for the twelve months ended December 31, 2025 as well as recent commercial and clinical updates.

IceCure is engaged with leading medical institutions throughout the U.S. looking to participate in the post-market study with the FDA-cleared ProSense® Clinical study sites may offer ProSense® cryoablation to additional patients not enrolled in the study, supporting its potential broader commercial adoption Post-market study will be conducted using cryoprobes sold exclusively by IceCure and facilities will be able to use CPT Category III reimbursement code CAESAREA, Israel, March 11, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that the U.S. Food and Drug Administration ("FDA") has approved the study design for the "ChoICE Trial Post-Market Study," the Company's post-marketing study for ProSense® in the treatment of low-risk breast cancer (the "Study").

CAESAREA, Israel, March 10, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the twelve months ended December 31, 2025 before the Nasdaq Stock Market opens on Tuesday, March 17, 2026.

IceCure's ICE3 study and the FDA Advisory Panel's favorable vote on ProSense® cryoablation's benefit-risk profile for low-risk breast cancer played a key role in the ASBrS 2026 Resource Guide update New medical society guidance expected to further accelerate commercial adoption of ProSense® following FDA-clearance for low-risk breast cancer in October 2025 CAESAREA, Israel, March 9, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that the American Society of Breast Surgeons' ("ASBrS") updated 2026 "Resource Guide on the Use of Transcutaneous and Percutaneous Ablation for the Treatment of Benign and Malignant Tumors of the Breast" recommends cryoablation as an option for selected patients with biologically low-risk early-stage breast cancer.

Treatment with ProSense® resulted in 92.9% volume reduction of fibroadenoma one-year post-cryoablation Findings may impact treatment guidelines issued by medical societies for large non-cancerous breast tumors; study is believed to be the first to evaluate larger lesions and use multiple cryoprobe relocations ProSense® Cryoablation has FDA-clearance for fibroadenomas CAESAREA, Israel, March 2, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the publication of an independent, investigator-initiated study evaluating ProSense® for the treatment of non-cancerous breast tumors,  or fibroadenomas.